SLC2A3 and myeloid sarcoma: Further molecular evidence of impaired glucose metabolism playing a role in MS is seen in the altered distribution of glucose (GLUT) and monocarboxylate transporters (MCT) within chronic lesions of MS where there is a decline in axonal GLUT3 and MCT2 expression.